HIMS Stock Up 13% on FDA Panel BPC-157 Recommendation

HIMS stock rallied 13% after an FDA advisory panel recommended adding BPC-157 to a list allowing compounding pharmacies to prepare it more freely.

The FDA panel voted in favor of expanding access to the peptide BPC-157, which is used for tissue repair.

The recommendation could boost compounding pharmacy revenue for HIMS.

The stock surge reflects investor optimism about potential increased demand for BPC-157 preparations.